Late-life depression: a neuropsychiatric approach

References

• Alexopoulos GS. Depression in the elderly. Lancet 365, 1961–1970 (2005).
   PubMed Web of Science ®Google Scholar
• •Excellent recent review on depression in the elderly.
   Google Scholar
• Alexopoulos GS, Buckwalterb K, Olin J, Martniz R, Wainscott C, Krishnan KRR. Comorbidity of late life depression: an opportunity for research on mechanisms and treatment. Biol. Psych. 15 52(6) 543–558 (2002).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Feldman HH, Jacova C. Mild cognitive impairment. Am. J. Geriatr. Psych. 13(8), 645–655 (2005).
   PubMedGoogle Scholar
• Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Masterman D, Ortiz F et al. Mild cognitive impairment associated with characteristic neuropsychiatric symptoms Alzheimer. Dis. Assoc. Disord. 18, 17–21 (2004).
   PubMed Web of Science ®Google Scholar
• Copeland MP, Daly E, Hines V et al. Psychiatric symptomatology and prodromal Alzheimer’s disease. Alzheimer Dis. Assoc. Disord. 17, 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 262(18), 2551–2556 (1989).
   PubMed Web of Science ®Google Scholar
• Chicot JV, Rajkumar S, Tanyakitpisal P et al. Alzheimer’s disease: of emerging importance. WHO Regional Health Forum, 6(1), 39–48 (2002).
   Google Scholar
• Zubenko GS, Zubenko WN, McPherson S et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am. J. Psych. 160, 857–866 (2003).
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Moossy J. Major depression in primary dementia; clinical and neuropathologic correlates. Arch. Neurol. 45, 1182–1186 (1988).
   PubMedGoogle Scholar
• Greenwald BS. Depression in Alzheimer’s disease and related dementias. In: Behavioral Complications of Alzheimer’s Disease. Lawlor BA (Ed.), American Psychiatric Press, WA, USA, 19–53 (1995).
   Google Scholar
• Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J. Am. Geriatr. Soc. 49(12), 1700–1707 (2001)
   PubMed Web of Science ®Google Scholar
• Marin RS. Differential diagnosis of apathy and related disorders of diminished motivation. Psych. Ann. 27, 30–33 (1990).
   Google Scholar
• Marin RS. Differential diagnosis and classification of apathy. Am. J. Psych. 147, 22–30 (1997).
   Google Scholar
• Royall DR. Frontal systems impairment in major depression. Semin Clin. Neuropsych. 4, 13–23 (1999).
   PubMedGoogle Scholar
• Olin J, Schneider LS, Katz IR et al. Provisional diagnostic criteria for depression of Alzheimer’s disease. Am. J. Geriatr. Psych. 10, 125–128 (2002).
   PubMed Web of Science ®Google Scholar
• Devanand DP, Sano M, Tang MX et al. Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch. Gen. Psych. 53(2), 175–182 (1996).
   PubMed Web of Science ®Google Scholar
• Jorm AF, van Duijn CM, Chandra V et al. Psychiatric history and related exposures as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2), S43–S47 (1991).
   PubMed Web of Science ®Google Scholar
• Geerlings MI, Schoeyers RA, Beekman AT et al. Depression and risk of cognitive decline and Alzheimer’s disease. Results of two prospective community-based studies in The Netherlands. Br. J. Psych. 176, 568–575 (2000).
   PubMed Web of Science ®Google Scholar
• Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch. Gen. Psych. 52(9), 735–746 (1995).
   PubMed Web of Science ®Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8), 1467–1472 (1993).
   PubMed Web of Science ®Google Scholar
• Kim DH, Payne ME, Levy RM, MacFall JR, Steffens DC. ApoE genotype and hippocampal volume change in geriatric depression. Biol. Psych. 51, 426–429 (2002).
   PubMed Web of Science ®Google Scholar
• Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 19(2–3), 154–157 (2005).
   PubMedGoogle Scholar
• Ballard CG, Cassidy G, Bannister C, Mohan RN. Prevalence, symptom profile, and etiology of depression in dementia sufferers. J. Affect. Disord. 29(1), 1–6 (1993).
   PubMed Web of Science ®Google Scholar
• Arkin S, Mahendra N. Insight in Alzheimer’s patients: results of a longitudinal study using three assessment methods. Am. J. Alzheimers. Dis. Other. Demen. 16(4), 211–224 (2001).
   PubMedGoogle Scholar
• Forstl H, Burns A, Luthert P et al. Clinical and neuropathological correlates of depression in Alzheimer’s disease. Psychol. Med. 22(4), 877–884 (1992).
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Moossy J, Koppu U Neurochemical correlates of major depression in primary dementia. Arch. Neurol. 47(2), 209–214 (1990).
   PubMedGoogle Scholar
• Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer’s disease: neurofibrillary tangles and loss of large neurons. Ann. Neurol. 17(6), 573–577 (1985).
   PubMedGoogle Scholar
• Bowen DM, Allen SJ, Benton JS et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J. Neurochem. 41(1), 266–272 (1983).
   PubMed Web of Science ®Google Scholar
• Rossor M, Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer’s disease. Br. Med. Bull. 42(1), 70–74 (1986).
   PubMed Web of Science ®Google Scholar
• Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease. Int. Psychogeriatr. 13(2), 233–240 (2001).
   PubMed Web of Science ®Google Scholar
• Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J. Neuropsych. Clin. Neurosci. 8(3), 270–275 (1996).
   PubMed Web of Science ®Google Scholar
• Roth M, Mountiov CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br. J. Psych. 168(2), 149–157 (1996).
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, DelCampo L, Steinberg M. Treating depression in Alzheimer’s disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch. Gen. Psych. 60(7), 737–746 (2003).
   PubMed Web of Science ®Google Scholar
• Papka M, Rubio A, Schifer RB et al. Lewy body disease: can we diagnose it? J. Neuropsych. Clin. Neuroscie. 10, 405–412 (1998).
   PubMed Web of Science ®Google Scholar
• Ballard C, Holmes C, McKeith I et al. Psychiatric morbidity in dementia with Lewy Bodies Am. J. Psych. 156, 1039–1045 (1999).
   PubMed Web of Science ®Google Scholar
• Ballard CG, Jacoby R, Teodoro DS et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy confirmed dementia with Lewy bodies. Am. J. Psych. 161, 843–849 (2004).
   PubMed Web of Science ®Google Scholar
• Ballard C, Holmes C, McKeith I et al. Psychiatric comorbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am. J. Psych. 156(7), 1039–1045 (1999).
   PubMed Web of Science ®Google Scholar
• Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 47(5), 1148–1152 (1996).
   PubMed Web of Science ®Google Scholar
• Perry EK, Irving D, Kerwin JM et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction to Alzheimer’s disease. Alzheimers Dis. Assoc. Disord. 7, 69–79 (1993).
   PubMed Web of Science ®Google Scholar
• Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst. Rev. (3), CD003672 (2003).
   PubMedGoogle Scholar
• Lanctôt KL, Herrmann N. Donepezil for behavioral disorders associated with Lewy bodies: a case series. Int. J. Geriatr. Psych.15(4), 338–345 (2000).
   PubMed Web of Science ®Google Scholar
• Simard M, van Reekum R. The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J. Neuropsych. Clin. Neurosci. 16(4), 409–425 (2004).
   PubMedGoogle Scholar
• Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann. NY Acad. Sci. 991, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov. Disord. 16(3), 507–510 (2001).
   PubMed Web of Science ®Google Scholar
• Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psych. 76(Suppl. 1), 148–152 (2005).
   Google Scholar
• Lemke MR, Fuchs G, Gemende I et al. Depression and Parkinson’s disease. J. Neurol. 251(Suppl. 6), VI/24–VI/27 (2004).
   Web of Science ®Google Scholar
• Cummings JL, Masterman DL. Depression in patients with Parkinson’s disease. Int. J. Geriatr. Psych. 14(9), 711–718 (1999).
   PubMed Web of Science ®Google Scholar
• Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov. Disord.17(3), 445–454 (2002).
   PubMedGoogle Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevelance studies of dementia in Parkinson’s disease. Mov. Disord. 20, 1255–1263 (2005).
   PubMedGoogle Scholar
• Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson’s disease. Arch. Neurol. 54(5), 625–630 (1997).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG. Depression in patients with early versus late onset of Parkinson’s disease. Neurology 39(11), 1441–1445 (1989).
   PubMed Web of Science ®Google Scholar
• Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: a possible subgroup of idiopathic Parkinsonism. Neurology 36(8), 1130–1133 (1986).
   PubMed Web of Science ®Google Scholar
• Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psych. 57(10), 1265–1267 (1994).
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38(9), 1402–1406 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J, McDermott M, Carter J et al. Variable expression of Parkinson’s disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10), 1529–1534 (1990).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Petracca G, Chemerinski E et al. Depression in classic versus akinetic-rigid Parkinson’s disease. Mov. Disord. 13(1), 29–33 (1998).
   PubMed Web of Science ®Google Scholar
• Tom T, Cummings JL. Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs Aging 12(1), 55–74 (1998).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Li YW, Blumbergs PC et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease. Ann. Neurol. 27(4), 373–385 (1990).
   PubMed Web of Science ®Google Scholar
• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and norepinephrine innervation in the limbic system. Brain 128(Pt 6), 1314–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Solinas C. Current approaches to management of depression in Parkinson’s disease. J. Clin. Neurosci. 12(7), 739–743 (2005).
   PubMed Web of Science ®Google Scholar
• Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE. Systematic review of antidepressant therapies in Parkinson’s disease. Parkinsonism Relat. Disord. 10(2), 59–65 (2003).
   PubMed Web of Science ®Google Scholar
• Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 49(4), 1168–1170 (1997).
   PubMed Web of Science ®Google Scholar
• van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Start of a selective serotonin re-uptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br. J. Clin. Pharmacol. 54(2), 168–170 (2002).
   PubMedGoogle Scholar
• Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord. 20(9), 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Antidepressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta. Neurol. Scand. 62(4), 210–219 (1980).
   PubMed Web of Science ®Google Scholar
• Mourik JC, Rosso SM, Niermijer MF et al. Frontemporal dementia: behavioral symptoms and caregiver distress. Dement. Geriatr. Cogn. Disord. 18, 299–306 (2004).
   PubMed Web of Science ®Google Scholar
• Swartz JR, Miller BL, Lesser IM et al. Frontotemporal dementia: treatment response to serotonin selective re-uptake inhibitors. J. Clin. Psych. 58(5), 212–216 (1997).
   Google Scholar
• Lebert F, Stekke W, Hasenbroekx C et al. Frontotemporal dementa: a randomized, controlled trial with trazadone. Dement. Geriatr. Cogn. Disord. 17(4), 355–359 (2004).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur. Neurol. 49(1), 13–19 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brian JT, Erkinjuntii T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol. 2(2), 89–98 (2003).
   PubMedGoogle Scholar
• Alexopoulos GS, Meyers BS, Young RC et al. ‘Vascular depression’ hypothesis. Arch. Gen. Psych. 54(10), 915–922 (1997).
   PubMed Web of Science ®Google Scholar
• de Groot JC, de Leuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch. Gen. Psych. 57(11), 1071–1076 (2000).
   PubMed Web of Science ®Google Scholar
• Steffens DC, Krishnan KR, Crump C, Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. Stroke 33(6), 1636–1644 (2002).
   PubMed Web of Science ®Google Scholar
• Burvill PW, Johnson GA, Jamrozik K et al. Prevalence of depression after stroke. Am. J. Psych. 166, 320–327 (1995).
   Google Scholar
• Whyte EM, Mulsant BH. Poststroke depression: epidemiology, pathophysiology and biological treatment. Biol. Psych. 52, 253–264 (2002).
   PubMed Web of Science ®Google Scholar
• Kales H, Maixner D, Mellow A. Cerebrovascular disease and late-life depression. Am. J. Geriatr. Psych. 13, 88–98 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson RG, Kubos KL, Starr LK. Mood disorders in stroke patients: importance of location of lesion. Brain 107, 81–93 (1984).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 110, 1045–1059 (1987).
   PubMed Web of Science ®Google Scholar
• Agrell B, Dehlin O. Depression in stroke patients with left and right hemisphere lesion. Aging 6, 49–56 (1994).
   PubMedGoogle Scholar
• Hackett M, Anderson C, House A. Management of depression after stroke. Stroke 36, 1092–1097 (2005).
   Web of Science ®Google Scholar
• Berg A, Psych L, Palomaki H et al. Poststroke depression: an 18 month follow-up. Stroke 34, 138–143 (2003).
   PubMed Web of Science ®Google Scholar
• Ramasubbu R. Cerebrovascular effects of selective serotonin re-uptake inhibitors: a systematic review. J. Clin. Psych. 65, 1642–1653 (2004).
   Google Scholar
• Fruehwald S, Gatterbauer E, Rehak P et al. Early fluoxetine treatment of post-stroke depression a three month double-blind placebo-controlled study with an open label long-term follow-up. J. Neurol. 250(3), 347–351 (2003).
   PubMed Web of Science ®Google Scholar
• Wiart L, Petit H, Joseph P et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31, 1829–1832 (2000).
   PubMed Web of Science ®Google Scholar
• Robinson R, Schultz S, Castillo C et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am. J. Psych. 157, 351–359 (2000).
   PubMed Web of Science ®Google Scholar
• Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am. J. Psych. 160, 1823–1829 (2003).
   PubMed Web of Science ®Google Scholar
• Niedermaier N, Bohrer E, Schulte K et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J. Clin. Psych. 65(12), 1619–1623 (2004).
   Google Scholar
• Palomaki H, Kaste M, Berg A et al. Prevention of post-stroke depression: 1 year randomised placebo-controlled double-blind trial of mianserin with 6 month follow-up after therapy. J. Neurol. Neurosurg. Psych. 66, 490–494 (1999).
   PubMed Web of Science ®Google Scholar